Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines

Vaccine

Volumn 26, Issue 39, 2008, Pages 5022-5029

  Xiao, Wenjun ^a   Du, Lanying ^b   Liang, Chao ^a   Guan, Jie ^a   Jiang, Shibo ^b   Lustigman, Sara ^b   He, Yuxian ^b,c   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

Activation associated protein 1; Adjuvant; Onchocerca volvulus; Vaccine

Indexed keywords

ACTIVATION ASSOCIATED PROTEIN 1; ALUMINUM POTASSIUM SULFATE; GLYCOPROTEIN GP 41; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; OVALBUMIN; RABIES VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOGENICITY; INTERFERON PRODUCTION; MALE; MOUSE; NONHUMAN; ONCHOCERCA VOLVULUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; HELMINTH PROTEINS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV; HIV ENVELOPE PROTEIN GP41; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; ONCHOCERCA VOLVULUS; OVALBUMIN; RECOMBINANT PROTEINS; TH1 CELLS; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 50549100718     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.028     Document Type: Article

References (24)

1. Weeratna R.D., Brazolot Millan C.L., McCluskie M.J., and Davis H.L. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 32 1 (2001) 65-71
2. Petrovsky N., and Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82 5 (2004) 488-496
3. Audibert F. Adjuvants for vaccines, a quest. Int Immunopharmacol 3 8 (2003) 1187-1193
4. Schmidt C.S., Morrow W.J., and Sheikh N.A. Smart adjuvants. Expert Rev Vaccines 6 3 (2007) 391-400
5. Bozza S., Gaziano R., Lipford G.B., Montagnoli C., Bacci A., Di Francesco P., et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microb Infect 4 13 (2002) 1281-1290
6. Ioannou X.P., Gomis S.M., Hecker R., Babiuk L.A., and van Drunen Little-van den Hurk S. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine 21 27-30 (2003) 4368-4372
7. Singh M., Ugozzoli M., Kazzaz J., Chesko J., Soenawan E., Mannucci D., et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24 10 (2006) 1680-1686
8. Visser A., Van Zeveren A.M., Meyvis Y., Peelaers I., Van den Broeck W., Gevaert K., et al. Gender-enriched transcription of activation associated secreted proteins in Ostertagia ostertagi. Int J Parasitol 38 3-4 (2008) 455-465
9. Goud G.N., Zhan B., Ghosh K., Loukas A., Hawdon J., Dobardzic A., et al. Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum. J Infect Dis 189 5 (2004) 919-929
10. Geldhof P., Meyvis Y., Vercruysse J., and Claerebout E. Vaccine testing of a recombinant activation-associated secreted protein (ASP1) from Ostertagia ostertagi. Parasite Immunol 30 1 (2008) 57-60
11. MacDonald A.J., Cao L., He Y., Zhao Q., Jiang S., and Lustigman S. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin. HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine 23 26 (2005) 3446-3452
12. MacDonald A.J., Tawe W., Leon O., Cao L., Liu J., Oksov Y., et al. Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity. Parasite Immunol 26 1 (2004) 53-62
13. Rey-Cuille M.A., Svab J., Benferhat R., Krust B., Briand J.P., Muller S., et al. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41. J Pharm Pharmacol 58 6 (2006) 759-767
14. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25 4 (2007) 763-775
15. Alignani D., Maletto B., Liscovsky M., Ropolo A., Moron G., and Pistoresi-Palencia M.C. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol 77 6 (2005) 898-905
16. Bisht H., Roberts A., Vogel L., Subbarao K., and Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 334 2 (2005) 160-165
17. Heraud J.M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 177 4 (2006) 2552-2564
18. Xiao Y., Aldaz-Carroll L., Ortiz A.M., Whitbeck J.C., Alexander E., Lou H., et al. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25 7 (2007) 1214-1224
19. Koide S., Yang X., Huang X., Dunn J.J., and Luft B.J. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J Mol Biol 350 2 (2005) 290-299
20. Dalakouras T., Smith B.J., Platis D., Cox M.M., and Labrou N.E. Development of recombinant protein-based influenza vaccine expression and affinity purification of H1N1 influenza virus neuraminidase. J Chromatogr A 1136 1 (2006) 48-56
21. Khajuria A., Gupta A., Malik F., Singh S., Singh J., Gupta B.D., et al. A new vaccine adjuvant (BOS 2000) a potent enhancer mixed Th1/Th2 immune responses in mice immunized with HBsAg. Vaccine 25 23 (2007) 4586-4594
22. Maizels R.M., and Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev 3 9 (2003) 733-744
23. Song E.S., Park S.A., Kim S.H., Cho Y.J., Ahn B.Y., Ahn B.C., et al. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen. FEMS Immunol Med Microbiol 51 3 (2007) 496-504
24. Pandit S., Cevher E., Zariwala M.G., Somavarapu S., and Alpar H.O. Enhancement of immune response of HBsAg loaded poly (l-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan. J Microencapsul 24 6 (2007) 539-552